Core Insights - Cygnus Biosciences has completed a new financing round exceeding 100 million yuan, aimed at ongoing R&D, product iteration, and expanding its commercial network, reflecting market confidence in domestic gene sequencing technology [2] - The company has developed a comprehensive core technology system, including Fluorogenic sequencing chemistry and microfluidic control, achieving self-sufficiency from chemical reactions to system integration [3] - Cygnus has launched two product series, offering not only instruments but also universal reagent kits and automated sample processing workstations, along with the "OpenSeq Project" for customizable sequencing solutions [5] Industry Expansion - Cygnus has obtained ISO13485 certification for medical devices, with applications in oncology, reproductive health, pathogen detection, and infectious disease prevention, collaborating with research institutions and hospitals [6] - The company plans to continue iterating on its product lines focused on desktop, diagnostic, and production models, aiming to enhance throughput and reduce costs, facilitating the clinical adoption of domestic sequencing instruments [6] - Investors highlight the potential for Cygnus to become a benchmark enterprise in the Beijing International Science and Technology Innovation Center, showcasing its competitive edge in domestic alternatives [6] Product Details - The S series (S100, S200) targets clinical and public health applications, with S100 receiving NMPA Class III registration and CE-IVDR certification, while S200 offers rapid results in pathogen detection [9] - The P series (P1000, P1000X) focuses on high-throughput research and multi-omics applications, with P1000X achieving a cost of $50 for a 30× human genome [9]